218 filings
Page 4 of 11
8-K
264702o zr
8 Mar 22
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results
7:01am
8-K
qslt5719
7 Mar 22
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
6:57am
8-K
34jg8vij dsgu
13 Dec 21
Optinose Announces Appointment of Two New Members to Board of Directors
8:38am
D
r51r7724v4 pahy
30 Nov 21
$4M in equity / options / securities to be acquired, sold $4M, 2 investors
9:44am
8-K
x2rd78ijkc z7ejw
18 Nov 21
Optinose Announces Proposed Public Offering of Common Stock
12:20pm
424B5
xjf1am68wffooixa0dv
18 Nov 21
Prospectus supplement for primary offering
7:30am
8-K
66m7c90je9b38
16 Nov 21
Entry into a Material Definitive Agreement
9:34am
8-K
wjwd9f i3lwdsx85j
16 Nov 21
Other Events
8:04am
424B5
qx52sp
15 Nov 21
Prospectus supplement for primary offering
5:26pm
8-K
bkbu1k7 jfj
15 Nov 21
Optinose Reports Third Quarter 2021 Financial Results
4:26pm
8-K
7u0qs l1wi
28 Oct 21
Other Events
7:00am
CT ORDER
9nmf4gs1dtt51ckodd3h
25 Oct 21
Confidential treatment order
9:04am
EFFECT
y3tgxig693mm43b7
1 Sep 21
Notice of effectiveness
12:15am
CORRESP
1bgjrde x81j0
23 Aug 21
Correspondence with SEC
12:00am
UPLOAD
396fxdg4
18 Aug 21
Letter from SEC
12:00am
8-K
8z7x9rzmtebax0w y7
11 Aug 21
Optinose Reports Second Quarter 2021 Financial Results
7:04am
8-K
ud7crmzp4wdqp70x0t9i
30 Jul 21
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
7:55am